Literature DB >> 23345303

18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.

Bianca A W Hoeben1, Esther G C Troost, Paul N Span, Carla M L van Herpen, Johan Bussink, Wim J G Oyen, Johannes H A M Kaanders.   

Abstract

UNLABELLED: This prospective study used sequential PET with the proliferation tracer 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) to monitor the early response to treatment of head and neck cancer and evaluated the association between PET parameters and clinical outcome.
METHODS: Forty-eight patients with head and neck cancer underwent (18)F-FLT PET/CT before and during the second and fourth weeks of radiotherapy or chemoradiotherapy. Mean maximum standardized uptake values for the hottest voxel in the tumor and its 8 surrounding voxels in 1 transversal slice (SUVmax(9)) of the PET scans were calculated, as well as PET-segmented gross tumor volumes using visual delineation (GTVVIS) and operator-independent methods based on signal-to-background ratio (GTVSBR) and 50% isocontour of the maximum signal intensity (GTV50%). PET parameters were evaluated for correlations with outcome.
RESULTS: (18)F-FLT uptake decreased significantly between consecutive scans. An SUVmax(9) decline ≥ 45% and a GTVVIS decrease ≥ median during the first 2 treatment weeks were associated with better 3-y disease-free survival (88% vs. 63%, P = 0.035, and 91% vs. 65%, P = 0.037, respectively). A GTVVIS decrease ≥ median in the fourth treatment week was also associated with better 3-y locoregional control (100% vs. 68%, P = 0.021). These correlations were most prominent in the subset of patients treated with chemoradiotherapy. Because of low (18)F-FLT uptake levels during treatment, GTVSBR and GTV50% were unsuccessful in segmenting primary tumor volume.
CONCLUSION: In head and neck cancer, a change in (18)F-FLT uptake early during radiotherapy or chemoradiotherapy is a strong indicator for long-term outcome. (18)F-FLT PET may thus aid in personalized patient management by steering treatment modifications during an early phase of therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345303     DOI: 10.2967/jnumed.112.105999

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

Review 1.  Imaging radiation response in tumor and normal tissue.

Authors:  Marjan Rafat; Rehan Ali; Edward E Graves
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

Review 2.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

Review 3.  The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.

Authors:  Giovanni Cammaroto; Natale Quartuccio; Alessandro Sindoni; Francesca Di Mauro; Federico Caobelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

Review 4.  Functional imaging in radiation therapy planning for head and neck cancer.

Authors:  Luis A Pérez Romasanta; María José García Velloso; Antonio López Medina
Journal:  Rep Pract Oncol Radiother       Date:  2013-11-09

5.  Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Michael A Deveau; Lyndsay Kubicek; Pamela White; Søren M Bentzen; Richard J Chappell; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

6.  Effectiveness of PET/CT with (18)F-fluorothymidine in the staging of patients with squamous cell head and neck carcinomas before radiotherapy.

Authors:  Radovan Vojtíšek; Jiří Ferda; Jindřich Fínek
Journal:  Rep Pract Oncol Radiother       Date:  2015-02-17

7.  18F-FLT and 18F-FDG PET-CT imaging in the evaluation of early therapeutic effects of chemotherapy on Walker 256 tumor-bearing rats.

Authors:  Weina Xu; Shupeng Yu; Jun Xin; Qiyong Guo
Journal:  Exp Ther Med       Date:  2016-11-03       Impact factor: 2.447

Review 8.  Applications of PET imaging with the proliferation marker [18F]-FLT.

Authors:  M Peck; H A Pollack; A Friesen; M Muzi; S C Shoner; E G Shankland; J R Fink; J O Armstrong; J M Link; K A Krohn
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-03-04       Impact factor: 2.346

9.  Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.

Authors:  Jennifer G Whisenant; J Oliver McIntyre; Todd E Peterson; Hakmook Kang; Violeta Sánchez; H Charles Manning; Carlos L Arteaga; Thomas E Yankeelov
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

10.  3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.

Authors:  Haojun Chen; Yimin Li; Hua Wu; Long Sun; Qin Lin; Long Zhao; Hanxiang An
Journal:  Strahlenther Onkol       Date:  2014-08-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.